Identifying urotropine derivatives as co-donors of formaldehyde and nitric oxide for improving antitumor therapy. Issue 61 (12th July 2021)

• Record Type: Journal Article
• Authors: Zhang, Yu; Feng, Shujun; Meng, Xia; Luo, Jun; Xu, Yurui; Ning, Xinghai
• Is Part Of: Chemical communications. Volume 57:Issue 61(2021)
• Page Start: 7581
• Page End: 7584
• Publication Date: 2021-07-12
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1039/d1cc02177j
• Languages: English
• ISSNs: 1359-7345

Abstract

Abstract : The first co-donor of formaldehyde and nitric oxide (FANO) was synthesized via pharmacophore integration strategy, which simultaneously generated NO and formaldehyde on-demand, resulting in synergistic anticancer effects both in vitro and in vivo . Abstract : A pharmacophore integration strategy was utilized to develop the first co-donor of formaldehyde and nitric oxide (FANO), composed of urotropine derived nitramine/nitrosamine. FANO simultaneously generated formaldehyde and nitric oxide on-demand, resulting in synergistic anticancer effects. Importantly, liposomal formulation of FANO effectively inhibited tumor growth with minimal side-effects, providing a potent combined nitric oxide therapy for malignancy.